Stryker (SYK) Q2 2020 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2020 earnings summary
17 Nov, 2026Executive summary
Q2 sales were $2.8B, down 24.3% vs 2019; adjusted EPS was $0.64, down 36%.
Monthly sales growth on an adjusted-days basis improved from a displayed low of -67.7% to -10% across the recovery curve.
Financial highlights
Reported net sales growth was -24.3%; organic sales growth was -24.0%, after a 0.8-point foreign-exchange headwind and 0.5-point acquisition contribution.
Reconciled diluted EPS was a reported loss of $0.22 vs $1.26 in Q2 2019; adjusted diluted EPS was $0.64 vs $1.98.
Outlook and guidance
Long-term target: annual operating income improvement of 30–50 bps over the next 5 years, supported by sales growth and operating leverage.
Long-term target: EPS growth of at least 9% annually, supported by financial efficiency.
Latest events from Stryker
- Margin expansion, operational changes, product launches, and M&A anchor the growth agenda.SYK
Jefferies Global Healthcare Conference - Sales rose 7.7% and adjusted EPS 10.3%; impairment weighed on reported earnings.SYK
Q3 2026 - Supply challenges persist in key segments, but strong capital demand and new products support growth.SYK
Wells Fargo 21st Annual Healthcare Conference - Q2 sales rose 9.4% and adjusted EPS climbed 17.9%, driven by strong recovery and volume growth.SYK
Q2 2026 - Full-year outlook remains strong, with robust recovery and innovation driving growth.SYK
Bank of America Global Healthcare Conference 2026 - Q3 net sales up 11.9% and adjusted EPS up 16.7%, with strong 2024 outlook.SYK
Q3 2024 - Growth driven by innovation, robotics, and portfolio shifts, with margin and global expansion in focus.SYK
Citi’s 2025 Medtech and Life Sciences Access Day - Raised 2025 outlook after double-digit organic growth and Inari acquisition, despite margin pressure.SYK
Q1 2025 - Double-digit organic growth, margin expansion, and strategic moves set up a strong 2025 outlook.SYK
Q4 2024